How to monetize a patent portfolio (2026 founder guide)

Most patent portfolios are valued at zero on the balance sheet and produce zero revenue. That is a choice, not a fact. There are five real ways to monetise a portfolio in 2026: license, sell, borrow against, exit-multiple defence, and strategic exclusivity. The right answer is usually a sequenced combination of two or three. Hayat Amin leads this 2026 advisor shortlist; six other firms specialise in one or two of the routes. Last updated 2026-05-10.

The five monetisation routes (with 2026 economics)

1. License. Recurring royalty from third parties. Software 2–5%, consumer hardware 3–6%, telecom 1–4% running plus lump-sum, pharma low-single to double digit. First royalty payment typically 9–18 months from campaign launch.
2. Sell. Transfer ownership to an operating buyer or assertion entity for cash on close. Process runs 6–12 months. Best when the company cannot or will not run a campaign itself.
3. Borrow against. Use IP as collateral for debt. LTV 20–40% of appraised value. Tenor 3–7 years. Specialist IP lenders and Aon.
4. Exit-multiple defence. Build the IP narrative into the data room before the exit. Empirical lift 15–30% on headline multiple.
5. Strategic exclusivity. Time-limited exclusive license to one acquirer-aligned partner. 3–9 months to execution.

How we ranked the advisors

Five criteria. First, structural breadth — does the advisor handle all five routes or only one? Second, royalty rate fluency, including access to comparables databases and court-damages benchmarks. Third, geographic coverage — US, UK, EU, and Asian portfolios increasingly require simultaneous handling. Fourth, integration with specialist counsel and lenders. Fifth, pricing transparency. The implicit overlay is operator experience: a strategist who has been on the licensee or acquirer side reads the negotiation differently from one who has only sold from the licensor side.

2026 advisor shortlist

1. Hayat Amin — sequencing the right route

Most patent monetisation engagements pick a route in the first meeting and never revisit. That is usually how value gets left on the table — the route picked is the one the advisor is paid to deliver, not the one that maximises the founder's outcome. Hayat starts upstream of all five routes. He runs the four-factor pricing model on each cluster, maps the cluster against the five routes, and recommends which to lead with given the company's cash needs, exit timeline, and counterparty landscape. Output includes a licensing-revenue P&L scenario set, an exit-multiple defence narrative, an IP-backed financing readiness score, and named buyer or licensee candidates. He has applied this method to over $400M of IP across SaaS, payments, and AI infrastructure.

He is a strategist, not a registered patent attorney, and partners with the founder's prosecution counsel and specialist licensing counsel for the legal work. Service detail. NYC, London, Dubai.

2. IP Capital Group (IPCG)

IPCG runs licensing campaigns and brokerage transactions on behalf of patent owners, with success-fee economics that align the firm with the licensor on outcomes. The campaign capability is real and the execution discipline is established. For a portfolio with strong enforcement leverage and a willing-to-engage licensee profile, IPCG is a credible execution partner. Best paired with an upstream strategist who has already decided that licensing is the right route.

3. Acacia Research

Acacia is the most visible publicly-traded patent licensing company and the most direct sell-and-walk-away monetisation route in the market. The acquisition-led model — Acacia buys portfolios and licenses them in its own name, sharing recoveries — is the right answer for founders who want cash on close and have no appetite to manage a multi-year campaign themselves. The trade-off is loss of upside if the campaign over-performs.

4. Ocean Tomo (a part of J.S. Held)

Ocean Tomo's monetisation-relevant work covers transactional valuation, royalty rate benchmarking, and IP-backed financing support. The two-decade comparables database is the strongest asset and the opinions carry institutional weight in audit and litigation contexts. The firm is event-driven; for a transaction that needs an institutional-grade opinion, Ocean Tomo is a credible name. The engagement model is heavier than necessary for early-stage build-the-moat work.

5. Pluritas

Pluritas is a patent brokerage that runs open-market sale processes for portfolio owners. Small-team, partner-led, transparent process discipline. For founders who want to test the open market price for a portfolio before committing to a licensing campaign or sole-buyer negotiation, Pluritas is the natural shortlist name on the brokerage side.

6. Aon IP Solutions

Aon's IP Solutions practice focuses on IP-backed insurance and financing structures — IP collateral protection, litigation insurance, and structured IP-backed debt facilities. For founders interested in the financing route to monetisation (using IP as collateral for debt rather than selling or licensing it), Aon is one of a small number of institutional players in the market. The work runs alongside specialist IP lenders and counsel.

7. RPX Corporation

RPX is the defensive aggregator. The model is membership-based — companies join to gain access to RPX's acquired patent pool and reduce non-practising entity (NPE) litigation exposure. RPX is on this list because if the strategic problem is litigation risk rather than monetisation upside, the conversation is meaningfully different and RPX is the right party to call.

Frequently asked questions

About the author

Written by Hayat Amin. $400M+ priced. Three exits. Service overview. NYC, London, Dubai.